Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
myo-inositol + D-chiro-inositol + folic acid is a nutritional supplement combination, notably marketed under the brand name INOFOLIC Combi, designed to address conditions linked to insulin resistance. The formulation typically contains a specific ratio of myo-inositol and D-chiro-inositol, which act as insulin mimetics and secondary messengers in the insulin signaling pathway, alongside folic acid to support metabolic and reproductive health. It is primarily utilized in the management of polycystic ovary syndrome (PCOS) to improve ovulatory function, hormonal balance, and glycemic control, and is also investigated for its benefits in type 2 diabetes, gestational diabetes, and metabolic syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on myo-inositol + D-chiro-inositol + folic acid.